首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
首頁 > 市場調查報告書 > 製藥 > 2007年製藥產業動向‐教訓
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

2007年製藥產業動向‐教訓

SPECIAL REPORT: 2007 Industry Dynamics - Lessons Learned

出版商 Decision Resources, Inc.
出版日期 2007年12月 商品編碼 58744
內容資訊 英文 39 Pages
價格
本報告書已不再販售

本報告已在2011年12月21日停止出版。

簡介

2007年的製藥產業的發展雖小有斬獲,同時也有著「一成不變的事業」的特徵。

本報告書內容包括:2007年度產業中主要事件的重要性評析、今後需要的策略、技術機會、新的價値提案、美國各州的影響等。內容綱要摘記如下:

第1章 實施概要

  • 策略考量事項
  • 利害關係人的影響

第2章 2007年總結

第3章 追求終極目的

第4章 2007年深刻影響製藥產業的主要新聞與事件

  • 2007年的藥物安全性相關問題
  • 大型製藥企業的生產效率問題
  • 進入市場的生物非專利藥品的影響
  • 專利到期的影響
  • 專業製藥企業及生物技術的優勢

第5章 控制支出及智慧的選擇

  • 暢銷藥品的數量雖逐漸增加,但成長幾乎停頓
  • 為了創造變化,需要企業經營的相關對策
  • 2家企業的經營型態:Pfizer及Schering-Plough
  • 智慧的選擇有著前所未有的重要性

第6章 掌握技術機會的趨勢

  • 追求創新:有益的技術機會:2007年左右
  • 製藥產業未來的活力來源

第7章 新的價值提案:成本效益

第8章 發展活躍的州勢力壯大

  • 2007年的教訓
  • 2007年的州法案
  • 害怕訴訟的州檢查總長

第9章 2007年範疇評分卡

第10章 Decision Resources, Inc.,的報告書

目錄

Abstract

Introduction

Moderate successes and "business as usual" characterize the performance of the pharmaceutical industry in 2007. In this year-end retrospective report, we contemplate the importance of key events and achievements in the industry. We asked industry-leading experts to identify particularly noteworthy events in 2007 and lessons that can be learned for 2008. Six themes emerged; our experts discuss their implications for the industry. Furthermore, we offer a Spectrum Scorecard that assesses industry performance in a variety of critical areas.

Get the Answers You Need to Shape Your Strategy

  • The pharmaceutical industry may never be to return to its glory days, but it can exert control over its future through the strategies and changes that it is willing to adopt today. What strategic options are essential to achieve success in today' s evolving markets? What are the future implications of these changes for pharmaceutical companies?
  • Pharmaceutical companies must ensure they are "fi t for purpose" in today' s business environment. What strategies can pharmaceutical management pursue to capture and harness the essence of a resultsoriented business and make their companies truly fi t for purpose? How can they uncover previously unrealizable profi ts and growth and also differentiate themselves so that they can grasp valuable competitive advantage?

Scope

  • 2007 in review: a retrospective on news and key themes from the year.
  • Seeking a new vision for the pharmaceutical industry: looking for the Holy Grail of opportunity.
  • Negative industry impacts: from generics erosion, biogenerics, declining productivity, and drug safety concerns combined with the increased importance of specialty pharma and biotech.
  • New strategies needed for future success: rethinking the blockbuster strategy, a holistic approach to management style, fi t with strategy, choosing strategies and opportunities wisely.
  • Jumping on technology opportunities: identifying key technologies and turning innovation into new products and services.
  • New value propositions: value-for-money.
  • Growing infl uence of U.S. states: legislative bills, litigation by state attorneys general, lessons learned.
  • 2007 industry report card: how successful was Big Pharma in capitalizing on the many opportunities available in 2007?

Table of Contents

  • Executive Summary
    • Strategic Considerations
    • Stakeholder Implications
  • 2007 in Review
  • Looking for the Grail
  • Noteworthy 2007 News and Events That Signifi cantly Impact the Pharmaceutical Industry
    • 2007' s Problems with Drug Safety
    • Big Pharma' s Ongoing Productivity Problems
    • Ramifi cations of Biogenerics Entering the Marketplace
    • Ramifi cations of Patent Expiries
    • Ascendancy of Specialty Pharma and Biotech
  • Retrenching and Choosing Wisely
    • Blockbuster Numbers Creep Upward, but Growth Grinds Almost to a Halt
    • Executing Change Requires a Holistic Approach to Managing a Company
    • A Tale of Two Management Styles: Pfi zer Versus Schering-Plough
      • Management Style
      • Insights from the Asenapine Story
      • Lessons to Be Learned About Management
    • Choosing Wisely Has Never Been More Important
  • Jumping on Technology Opportunities
    • The Quest for Innovation: Valuable Technology Opportunities, Circa 2007
    • Future Lifeblood of the Pharmaceutical Industry
  • New Value Propositions: Value-for-Money
  • Increasing Power of Activist States
    • 2007 Lessons to Be Learned
    • 2007 State Legislative Bills
    • State Attorneys General Not Afraid to Litigate
  • 2007 Spectrum Scorecard
  • Showcase of Decision Resources, Inc., Reports and Presentations

Tables

  • 1. Products Gaining Blockbuster Status, 2006
  • 2. The New Mantra: A Strategy of Focus, Late 2006-2007
  • 3. State Activities That Will Impact the Pharmaceutical Industry Going Forward
  • 4. Spectrum Scorecard: Pharmaceutical Industry Performance, 2007

Figures

  • 1. The Perceived Value of Biotech Is Real: Growth in AMEX Indices, 2004-2007
  • 2. Growth in the Number of Global Blockbusters, 1987-2006
  • 3. Years on the Market to Reach Blockbuster Status
  • 4. Components Central to Executing Change in a Pharmaceutical Company
  • 5. U.S. Oncology Leaders, 2000 and 2005
  • 6. A Blazing Mergers and Acquisition Trail for Antibody Companies, 2005-2007
  • 7. Prescription Drug State Legislation, 2007
Back to Top